Boehringer Ingelheim Espana S.A.

Interstitial lung disease and fibrotic lung disorders

Research activity includes idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, progressive fibrosing interstitial lung diseases, and systemic sclerosis-associated interstitial lung disease, with additional interest in rheumatic disease-related lung fibrosis and lung function decline.

  • Pulmonary fibrosis
  • Interstitial lung disease
  • Systemic sclerosis
  • Respiratory symptom burden

Additional work extends to cough in fibrotic lung disease and related respiratory impairment.

Dermatology and immune-mediated skin disease

The sponsor funds studies in generalized pustular psoriasis, hidradenitis suppurativa, pyoderma gangrenosum, and Netherton syndrome, reflecting a strong focus on severe inflammatory and rare dermatologic conditions.

  • Generalized pustular psoriasis
  • Hidradenitis suppurativa
  • Pyoderma gangrenosum
  • Netherton syndrome

Interest also includes recurrent flares and longer-term management of chronic skin inflammation.

Clinical research spans non-small cell lung cancer, small cell lung carcinoma, HER2-driven solid tumours, pancreatic cancer, biliary tract cancer, urothelial bladder cancer, glioblastoma, glioma, and dedifferentiated liposarcoma.

  • HER2-mutated cancers
  • Advanced solid tumours
  • Pancreatic and biliary cancers
  • Neuro-oncology

Further activity covers extrapulmonary neuroendocrine carcinoma and other advanced malignancies.

Kidney disease, cardiometabolic disease, and heart failure

Research includes chronic kidney disease, proteinuric kidney disease, focal segmental glomerulosclerosis, and other glomerular disorders, alongside studies in type 2 diabetes, obesity, hypertension, and cardiovascular disease.

  • Chronic kidney disease
  • Glomerular disease
  • Type 2 diabetes
  • Cardiovascular risk

Additional interest extends to myocardial infarction, heart failure, and obesity-related metabolic disease.

Liver disease, cystic fibrosis, and rare inflammatory disorders

The portfolio also covers portal hypertension in cirrhosis, including clinically significant portal hypertension, as well as cystic fibrosis and cystic fibrosis-related bronchiectasis. Rare immune and inflammatory conditions such as systemic lupus erythematosus and type 1 interferonopathies are also represented.

  • Portal hypertension
  • Cirrhosis
  • Cystic fibrosis
  • Autoimmune disease

Work in bronchiectasis and related chronic airway disease further broadens the respiratory research focus.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

    Recruiting

    3 1 1
    Investigated diseases:
    Austria Belgium Croatia Czechia Denmark Estonia +14
  • Study on Long-Term Safety of BI 907828 for Patients with Solid Tumors Who Previously Participated in a Study with This Medicine

    Recruiting

    2 1 1
    Investigated diseases:
    Belgium Czechia Denmark France Germany Hungary +5
  • Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Austria Belgium Czechia Denmark Finland France +8
  • A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

    Not yet recruiting

    3 1 1 1
    Austria Belgium Bulgaria Czechia Estonia Finland +14
  • Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

    Not yet recruiting

    3 1 1 1
    Austria Belgium France Germany Greece Hungary +7
  • Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium Czechia France Germany Italy The Netherlands +2